EUVIMEDEUVIMED entdecken
Crossref

Development and Validation of a QbD-Based Stability-Indicating HPLC Method with LC–MS Characterization of Nirmatrelvir in Bulk Drug and Pharmaceutical Formulation

Surekha Shegar, Dr. Minal Ghante, Mr. Pravin Sake

International Journal of Drug Delivery Technology · 20.04.2026 · 16 (14s)

DOI: 10.25258/ijddt.16.14s.93 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 20.04.2026. Verfasst von Surekha Shegar und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to develop and validate a quality by design (QbD)–based stability-indicating HPLC method for the quantitative determination of nirmatrelvir in bulk drug and pharmaceutical formulations, along with LC–MS characterization of its degradation products.

Methods

Method development was carried out using a QbD approach supported by central composite design to optimize critical chromatographic parameters. Forced degradation studies were performed under acidic, alkaline, oxidative, thermal, and photolytic conditions in accordance with ICH guidelines. Chromatographic separation was achieved on a NucleoSil C8 column (250 × 4.6 mm, 5 μm) using an isocratic mobile phase of methanol and 0.1% formic acid (70:30, v/v) at a flow rate of 1.2 mL/min, with UV detection at 215 nm. The method was validated for linearity, accuracy, precision, specificity, robustness, and sensitivity. Degradation products were characterized using LC–MS.

Results

Nirmatrelvir showed significant degradation under acidic and alkaline conditions, forming three major degradation products (DP1, DP2, and DP3), while minimal degradation was observed under oxidative, thermal, and photolytic stress. The retention time of nirmatrelvir was 4.037 min. The method demonstrated excellent linearity over the concentration range of 4–24 μg/mL (R² = 0.999), with satisfactory accuracy (recoveries close to 100%), precision (%RSD < 2), robustness, and specificity. The limits of detection and quantification were 0.646 μg/mL and 1.957 μg/mL, respectively. LC–MS analysis enabled structural characterization of the degradation products and proposal of probable degradation pathways.

Conclusion

A robust, precise, and stability-indicating QbD-based HPLC method was successfully developed and validated for nirmatrelvir. The method effectively separates the drug from its degradation products and is suitable for routine quality control and stability studies of nirmatrelvir in bulk drug and pharmaceutical formulations.

Zitieren

APA

Shegar, S., Ghante, D. M., & Sake, M. P. (2026). Development and Validation of a QbD-Based Stability-Indicating HPLC Method with LC–MS Characterization of Nirmatrelvir in Bulk Drug and Pharmaceutical Formulation. International Journal of Drug Delivery Technology, 16(14s). https://doi.org/10.25258/ijddt.16.14s.93

Vancouver

Shegar S, Ghante DM, Sake MP. Development and Validation of a QbD-Based Stability-Indicating HPLC Method with LC–MS Characterization of Nirmatrelvir in Bulk Drug and Pharmaceutical Formulation. International Journal of Drug Delivery Technology. 2026;16(14s). doi:10.25258/ijddt.16.14s.93

BibTeX
@article{Shegar2026,
  author = {Shegar, Surekha and Ghante, Dr. Minal and Sake, Mr. Pravin},
  title = {Development and Validation of a QbD-Based Stability-Indicating HPLC Method with LC–MS Characterization of Nirmatrelvir in Bulk Drug and Pharmaceutical Formulation},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {14s},
  doi = {10.25258/ijddt.16.14s.93}
}
Kostenlos starten →